Search | OpenScholar

Search results

193 results found

Randomized Trial of Preladenant, Given as Monotherapy, in Patients with Early Parkinson Disease. Neurology 2017;88:2198-2206.

Publication: Journal Article

Stocchi, F, O Rascol, RA Hauser, S Huyck, A Tzontcheva, R Capece, TW Ho, et al. 2017. “Randomized Trial of Preladenant, Given As Monotherapy, in Patients With Early Parkinson Disease. Neurology 2017;88:2198-2206.”. Neurology.

Factors associated with falling in early, treated Parkinson's disease: The NET-PD LS1 cohort. J Neurol Sci 2017;377:137-143.

Publication: Journal Article

Chou, KL, JJ Elm, CL Wielinski, DK Simon, MJ Aminoff, CW Christine, GS Liang, RA Hauser, L Sudarsky, and . 2017. “Factors Associated With Falling in Early, Treated Parkinson’s Disease: The NET-PD LS1 Cohort. J Neurol Sci 2017;377:137-143.”. J Neurol Sci.

ADS-5102 (Amantadine) Extended-Release Capsules for Levodopa-Induced Dyskinesia in Parkinson Disease (EASE LID Study): A Randomized Clinical Trial. JAMA Neurol 2017;74:941-949.

Publication: Journal Article

Pahwa, R, CM Tanner, RA Hauser, SH Isaacson, PA Nausieda, DD Truong, P Agarwal, et al. 2017. “ADS-5102 (Amantadine) Extended-Release Capsules for Levodopa-Induced Dyskinesia in Parkinson Disease (EASE LID Study): A Randomized Clinical Trial. JAMA Neurol 2017;74:941-949.”. JAMA Neurol.

ADS-5102 (Amantadine) Extended-Release Capsules for Levodopa-Induced Dyskinesia in Parkinson's Disease (EASE LID 2 Study): Interim Results of an Open-Label Safety Study. J Parkinsons Dis 2017;7:511-522.

Publication: Journal Article

Hauser, RA, R Pahwa, CM Tanner, W Oertel, SH Isaacson, R Johnson, L Felt, and MJ Stempien. 2017. “ADS-5102 (Amantadine) Extended-Release Capsules for Levodopa-Induced Dyskinesia in Parkinson’s Disease (EASE LID 2 Study): Interim Results of an Open-Label Safety Study. J Parkinsons Dis 2017;7:511-522.”. J Parkinsons Dis.

Preladenant as an Adjunctive Therapy With Levodopa in Parkinson Disease: Two Randomized Clinical Trials and Lessons Learned. JAMA Neurol 2015;72:1491-500.

Publication: Journal Article

Hauser, RA, F Stocchi, O Rascol, SB Huyck, R Capece, TW Ho, P Sklar, C Lines, D Michelson, and D Hewitt. 2015. “Preladenant As an Adjunctive Therapy With Levodopa in Parkinson Disease: Two Randomized Clinical Trials and Lessons Learned. JAMA Neurol 2015;72:1491-500.”. JAMA Neurol.

Correlates of excessive daytime sleepiness in de novo Parkinson's disease: A case control study. Mov Disord 2015;30:1371-81.

Publication: Journal Article

Simuni, T, C Caspell-Garcia, C Coffey, LM Chahine, S Lasch, WH Oertel, G Mayer, et al. 2015. “Correlates of Excessive Daytime Sleepiness in de Novo Parkinson’s Disease: A Case Control Study. Mov Disord 2015;30:1371-81.”. Mov Disord.

Droxidopa in patients with neurogenic orthostatic hypotension associated with Parkinson's disease (NOH306A). J Parkinsons Dis 2014;4:57-65.

Publication: Journal Article

Hauser, RA, LA Arthur Hewitt, and S Isaacson. 2014. “Droxidopa in Patients With Neurogenic Orthostatic Hypotension Associated With Parkinson’s Disease (NOH306A). J Parkinsons Dis 2014;4:57-65.”. J Parkinsons Dis.

Double-blind study of the actively transported levodopa prodrug XP21279 in Parkinson's disease. Mov Disord 2014;29:75-82.

Publication: Journal Article

LeWitt, PA, FJ Huff, RA Hauser, D Chen, D Lissin, K Zomorodi, and KC Cundy. 2014. “Double-Blind Study of the Actively Transported Levodopa Prodrug XP21279 in Parkinson’s Disease. Mov Disord 2014;29:75-82.”. Mov Disord.

Randomized, placebo-controlled trial of trimethobenzamide to control nausea and vomiting during initiation and continued treatment with subcutaneous apomorphine injection. Parkinsonism Relat Disord 2014;20:1171-6.

Publication: Journal Article

Hauser, RA, S Isaacson, T Clinch, and Tigan/Apokyn Study Investigators. 2014. “Randomized, Placebo-Controlled Trial of Trimethobenzamide to Control Nausea and Vomiting During Initiation and Continued Treatment With Subcutaneous Apomorphine Injection. Parkinsonism Relat Disord 2014;20:1171-6.”. Parkinsonism Relat Disord.

Success rate, efficacy, and safety/tolerability of overnight switching from immediate- to extended-release pramipexole in advanced Parkinson's disease. Eur J Neurol 2013;20:180-7.

Publication: Journal Article

AH, Schapira, P Barone, RA Hauser, Y Mizuno, O Rascol, M Busse, C Debieuvre, M Fraessdorf, and W Poewe. 2013. “Success Rate, Efficacy, and Safety/Tolerability of Overnight Switching from Immediate- to Extended-Release Pramipexole in Advanced Parkinson’s Disease. Eur J Neurol 2013;20:180-7.”. Eur J Neurol.